Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ALDH3A1/IL-17 axis in preparation of medicine for treating refractory ulcer

A technology for refractory ulcers and drugs, applied in the field of biomedicine, can solve problems such as carcinogenicity, easy degradation, and unbearable for patients, and achieve the effect of reducing inflammatory infiltration and enhancing cell proliferation

Active Publication Date: 2022-02-15
SHANGHAI DERMATOLOGY HOSPITAL
View PDF6 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, only platelet-derived growth factor (PDGF-BB) has been approved by the US FDA for wound healing, but because of its high price, patients are often unaffordable
Although other growth factor preparations (EGF, bFGF) have certain curative effects, there are problems such as easy degradation, inconvenient drug storage, and easy to cause hypertrophic scars, which limit their popularization and application; there are even reports that some new excipients have certain carcinogenic risks

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ALDH3A1/IL-17 axis in preparation of medicine for treating refractory ulcer
  • Application of ALDH3A1/IL-17 axis in preparation of medicine for treating refractory ulcer
  • Application of ALDH3A1/IL-17 axis in preparation of medicine for treating refractory ulcer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] 1. Methods and Materials

[0049] 1. Cell culture and transfection

[0050] The human keratinocyte cell line HaCaT was purchased from Cell Lines Service, Eppelheim, Germany. Cells were cultured in DMEM-high glucose (4.5 g / L, Gibco, Life Technologies, Carlsbad, CA) containing 10% (v / v) fetal bovine serum (HyClone, Logan, UT, USA) and 1% ( v / v) Streptomycin-penicillin solution (10000 U / mL, Gibco, Life Technologies) with or without 20 ng / ml bFGF (basic fibroblast growth factor, ThermoFisher Science, #13256029) at 37°C Constant temperature culture.

[0051] ALDH3A1-overexpressed HaCaT cells were constructed using a lentiviral transfection system. Using DNAFect transfection reagent (109120002, HarOLife, Shanghai, China), 1.7 μg ALDH3A1 overexpression vector (backbone plasmid is pLVX-IRES-Puro (Catalog No.632183, Clontech, US), see figure 1 , the ALDH3A1 sequence directional cloned into the vector backbone is shown in SEQ ID NO: 7, the insertion site is EcoRI / NotI) or CMV...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of an ALDH3A1 / IL-17 axis in preparation of a medicine for treating refractory ulcer. According to the invention, proteomics is combined with biological information analysis, and experimental verification is combined for use, so the protein expression of ALDH3A1 in a wound surface of a db / db diabetic mouse is reduced; and by overexpressing ALDH3A1 expression in HaCaT cells, proliferation of the cells is increased, inflammatory infiltration is relieved, and an IL-17 pathway is remarkably inhibited. It is prompted in the invention that ALDH3A1 can improve chronic inflammation, promote cell proliferation and heal wounds by inhibiting downstream IL-17 signal channels, and the targeted ALDH3A1 / IL-17 axis can be used as a novel treatment method and is used for treating refractory ulcers, chronic inflammation after injury, infection and other types of wounds in the future.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of the ALDH3A1 / IL-17 axis in the preparation of refractory ulcer medicine. Background technique [0002] The skin is the organ that the human body has the most contact with the environment, and is directly exposed to the surrounding environment. It has functions such as sensory and immune protection, and is also vulnerable to injury and infection. Wound healing is impaired in diabetes, vascular disease, and elderly patients. Diabetic ulcers (DUs) are a serious complication of diabetes, which often occur on the feet of patients, so they are also called diabetic feet. The disability rate and recurrence rate are extremely high, and the incidence rate increases year by year along with the increase in the prevalence of diabetes. Clinical studies have shown that by controlling blood sugar levels and wound infection, DUs still take a long time to heal, and the woun...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K38/44A61P17/02A61P29/00A61P3/10A61P31/00G01N33/68C12Q1/6883
CPCA61K45/00A61K38/44A61P17/02A61P29/00A61P3/10A61P31/00C12Y102/0101C12Q1/6883G01N33/6893G01N2800/042C12Q2600/158
Inventor 李斌蒯仂向延卫江静斯茹意罗楹马晓萱张颖陈启龙朱全刚白云王瑞平宋建坤罗月费晓雅丁晓杰位磊陈思婷张展杨丹薛婷婷
Owner SHANGHAI DERMATOLOGY HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com